IFN-α16 Activators are a distinct chemical class focused on the specific modulation of interferon-alpha 16 (IFN-α16), a member of the type I interferon family, pivotal in the innate immune response. These activators aim to enhance the function of IFN-α16 by increasing its expression, stability, or facilitating its interaction with the interferon-α receptor (IFNAR), which then triggers a signaling cascade resulting in the upregulation of interferon-stimulated genes (ISGs). These genes orchestrate a range of immune responses aimed at maintaining cellular homeostasis and defending against pathogens. The specificity of these activators is paramount, as they are designed to selectively target IFN-α16, thereby fine-tuning the immune signaling pathways without cross-reacting with other interferon subtypes or immune mediators.
The discovery and mechanistic understanding of IFN-α16 Activators involve a synergistic approach that blends techniques from molecular biology, immunology, and biochemistry. This begins with high-throughput screening of potential activators that can modulate IFN-α16, followed by assays to elucidate their interaction with IFNAR and their impact on IFN-α16's post-translational modifications. Subsequent cellular assays focus on the activators' influence on ISG expression and the establishment of an antiviral cellular state, using advanced genomic profiling and viral challenge assays. Furthermore, the investigation encompasses the analysis of key signaling molecules and transcription factors within the interferon signaling pathway, such as STAT1 and STAT2, to fully elucidate the biological consequences of IFN-α16 activation at the molecular level, thus contributing to a deeper understanding of the regulation of immune responses.
SEE ALSO...
Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
---|---|---|---|---|---|---|
Imiquimod | 99011-02-6 | sc-200385 sc-200385A | 100 mg 500 mg | $66.00 $278.00 | 6 | |
An immune response modifier that acts as an agonist of TLR7, potentially leading to the induction of type I interferons like IFN-α16. | ||||||
Gardiquimod | 1020412-43-4 | sc-221663 sc-221663A sc-221663B sc-221663C sc-221663D sc-221663E sc-221663F | 25 mg 50 mg 100 mg 250 mg 5 g 10 g 25 g | $154.00 $276.00 $506.00 $1154.00 $19743.00 $32136.00 $69366.00 | 1 | |
A specific TLR7 agonist that may mimic viral single-stranded RNA, potentially stimulating the production of type I interferons. | ||||||
R-848 | 144875-48-9 | sc-203231 sc-203231A sc-203231B sc-203231C | 5 mg 25 mg 100 mg 500 mg | $100.00 $300.00 $500.00 $1528.00 | 12 | |
An agonist for TLR7 and TLR8 that can induce the production of type I interferons, including IFN-α16, as part of the antiviral response. | ||||||
Loxoribine | 121288-39-9 | sc-203118 sc-203118A | 25 mg 100 mg | $124.00 $390.00 | 1 | |
A TLR7 agonist that might stimulate the innate immune system to produce type I interferons, such as IFN-α16. | ||||||
Ribavirin | 36791-04-5 | sc-203238 sc-203238A sc-203238B | 10 mg 100 mg 5 g | $62.00 $108.00 $210.00 | 1 | |
An antiviral drug that has been shown to induce IFN-α in some settings, potentially including IFN-α16, through immune modulation. |